HC Wainwright reaffirmed their buy rating on shares of Clovis Oncology (NASDAQ:CLVS) in a research report released on Wednesday, July 3rd, Stock Target Advisor reports. “Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, …
Read More »Clovis Oncology (NASDAQ:CLVS) Given “Buy” Rating at HC Wainwright
